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but newer evidence suggests it is more common. Less than 15% of FH patients are ever 
diagnosed with children and young adults rarely tested despite having most to gain given 
their lifetime exposure. 
Increasing awareness among primary care teams is critical to improve detection profile for 
FH. Cascade testing in the community setting needs a sustainable approach to be 
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in Australia and eliminates the need to undertake genetic testing for all suspected FH cases. 
Keywords: Familial hypercholesterolaemia, Cardiovascular disease, Prevalence, Statins, 
Primary - Tertiary care management, Index case, Cascade testing, Dutch Lipid Clinic 
Network Criteria, Phenotypic testing 
Expert CommentaryBody of Article 
Public health burden 
Awareness that inherited factors can play a significant part in the development of 
atherosclerotic cardiovascular disease (CVD) is generally not well appreciated amongst the 
general population in Australia. Whilst it is often well known among family members and 
other more distant relatives that premature deaths attributed to heart disease have occurred 
in their families, the significance of such events in relation to their personal risk is often not 
fully understood and easily forgotten. It is against such a background that attempts to 
achieve a higher profile for CVD risk assessment have often met with very limited success. 
Familial hypercholesterolaemia (FH) is an autosomal dominant inherited condition [1] that 
causes significantly raised total and low-density lipoprotein cholesterol (LDL-c) levels in 
affected individuals from birth. Individuals with heterozygous FH (HeFH) have a 50% chance 
of passing the condition to their offspring. The lifelong exposure to high circulating lipids 
significantly increases their chances of developing premature CVD and death.[2] For males 
with HeFH, the risk of developing coronary heart disease before age 50 years is 50% while 
for females it is 30% before age 60 years.[3, 4] The CVD risk for individuals with 
homozygous FH (HoFH) is much greater. Left untreated these patients may manifest CVD 
events and other vascular complications in childhood or adolescence.[5] 
The marked acceleration of coronary artery disease (CAD) seen with FH means that the 
young have much to gain from early diagnosis and treatment.  Effective and early treatment 
of FH with statin therapy reduces the lifetime exposure to very high cholesterol levels with 
the concomitant reduction in CVD events largely offsetting the cost of prolonged 
treatment.[6, 7] The key therefore is to detect and treat FH as early as possible. 
The prevalence for FH was generally reported as 1:500 [1, 3, 8] but more recent European 
[9, 10] and Australian [11] research suggests it is more common in the general population. 
FH is also especially frequent among communities exhibiting founder gene effects.[3] [1] In 
countries such as Australia with historically high immigration rates the possibility of 
increased FH presence amongst patients from such communities should always be 
considered. The prevalence of FH amongst indigenous Australians is unkown. 
The majority of FH cases are caused by mutations in the gene encoding the LDL-receptor 
(LDLR) while less common mutations in the apolipoprotein-B (apo-B) and Proprotein 
convertase subtilisin/kexin type 9 (PCSK9) genes cause similar functional consequences.[2] 
[12] There are over 1200 mutations known to cause FH,[13] and testing for all mutations is 
not practical. Currently a mutation is only detected in 60-90% of individuals with clinically 
definite FH.[14] Thus, failure to detect a mutation does not exclude a diagnosis of FH. This 
makes genetic testing for population screening purposes less feasible, expensive and 
controversial, both for patients and the health systems involved.  
Low detection rates in children and young adults  
Despite this potential for early intervention, less than 15% of patients with FH are ever 
diagnosed [8] with children, teenagers and those aged 20 - 40 years amongst the least likely 
to be offered opportunistic lipid testing during routine primary care visits. This occurs 
principally because most of these patients are not recognised as potentially at risk, and do 
not routinely have serum cholesterol estimations undertaken – at least not until much later in 
middle adult life.  
Similarly, because of poor awareness of FH,[15] children of FH patients are often not 
recognised as being at risk, or in need of early diagnosis and management to prevent 
development of CAD. Their plight is often compounded by reluctance on the part of the 
primary care physician to institute appropriate treatment at an early age (from age 10 years 
in boys and one year post menarche in girls is recommended [16]). This is sometimes 
exacerbated by a certain ‘statin stigma’ and attacks on the efficacy of such medication in the 
popular media.[17, 18] This situation is unlikely to change unless the profile of the condition 
receives much greater prominence and the benefits and cost effectiveness of early 
intervention are brought to the attention of patients, General Practitioners (GPs), Practice 
Nurses (PNs) and primary care teams.  
Absolute and relative CVD risk in FH patients 
In assessing CVD risk, it is important for clinicians to be aware of the potential presence of 
FH in patients whose lipid results show very elevated LDL-c levels. Absolute CVD risk 
calculators are not advised in FH patients as they underestimate risk for this condition that 
has been present from birth. The relative risk posed by markedly raised LDL-c levels in 
patients with FH is so great that the over-riding significance of this single risk factor needs to 
be acknowledged and such patients should be treated with lifelong, maximum tolerated 
statins with or without ezetimibe. An LDL-c level above 5.0mmol/L should raise a high 
degree of suspicion for the presence of FH and clinicians should flag such patients for 
careful assessment and management. Patients with personal or family history of CVD and 
untreated LDL-c level above 4mmol/l should also be considered for assessment of FH risk. 
It is estimated that the ‘cholesterol-life years burden’ accumulated by a patient with FH at 
age 45 years is roughly equivalent to that of a similar patient without FH by age 70 years.[19, 
20] Effective treatment is available with statin therapy and such treatment is most beneficial 
and cost effective for younger patients as they have not yet developed severe 
atherosclerosis due to the lower exposure to elevated LDL-c, and thus severe 
atherosclerosis may be prevented. 
Unique features of primary care populations 
In Australia, over 81% of the population consult a GP annually [21] with GPs requesting 
91.8% of all LDL-c tests undertaken through a community based pathology laboratory.[22] 
Research has shown that it may be possible to use a serum LDL-c cut-off point alone to 
facilitate detection of FH [23, 24] with GP consultations potentially offering unique 
opportunity to help detect unknown index cases of FH in the community.[25]   
Current Australian State and Federal Government policy aims to increase primary care 
management of most chronic conditions. The ensuing increase in time and resource 
implications means that a primary care based model of care (MoC) for FH needs to be 
simple, efficient and sustainable.  
Data from the Bettering the Evaluation and Care of Health (BEACH) studies show that only 
5.3% of patients seen by GPs are referred for specialist management.[26] Whilst GPs refer 
selected populations to their specialist colleagues, they themselves constantly sift diseases 
that often present in very early stages and are exposed to major serious illnesses 
infrequently.[27] This information is critical to appreciate the different demographics of the 
unselected, undifferentiated populations and presentations seen in primary care compared 
to the highly selective, well differentiated populations referred to specialists for tertiary level 
care. The primary care physician requires considerable adaptability and flexibility to meet the 
health needs of individual patients often with multiple morbidities [28-30] and contrasts with 
the specialist tertiary clinic that deals with the health needs of a group of patients all with 
same range of diseases or illnesses.  
In essence, much of the work of primary care physicians is grounded in knowledge that 
incorporates biomedical, social, psychological, interpersonal and intrapersonal 
perspectives.[27] For GPs, the consultation is much more patient-centred rather than 
disease focussed and offers a comprehensive, holistic approach to care that is not just 
community based but also offers an opportunity to incorporate unique sociological as well as 
environmental aspects to patient care. Their knowledge of patient and family history can 
often transcend generations as well as care for extended families. 
However, taking a family history and recording it in patient records is usually poorly 
documented in primary care with the average time taken for family history discussion being 
less than three minutes.[31, 32] Better systems are needed to assist primary care clinicians 
to include comprehensive family history records and to ensure such histories are regularly 
updated.  
Against such a background, the involvement of primary care in the early recognition and 
management of FH offers both challenges and opportunities. High on the list of opportunities 
must be the ability to help detect the condition in younger patients who have inherited FH but 
have never been screened, never formally diagnosed or offered appropriate treatment.  
Opportunities in primary care 
Primary care is recognised as being ideally placed to provide a more important role in both 
opportunistic and systematic case finding especially in recognising the association between 
premature coronary heart disease (CHD) and markedly elevated serum cholesterol 
concentrations.[8, 15, 33] An analysis of the cost effectiveness of different approaches to 
screening for FH found that targeting family members was the most successful option and 
far superior to simply targeting patients admitted to hospital with premature myocardial 
infarction.[34] When this approach is combined with institution of treatment with lipid-
lowering agents and subsequent targeted referral of high risk cases for specialist lipid 
management, the outcome is to substantially reduce morbidity and mortality from CHD 
among younger FH patients.[35] 
The presence of other cardiovascular risk factors is recognised in individuals with FH, 
although these conditions are also normally managed in the primary care setting, such as 
smoking, obesity, excess alcohol intake, lack of exercise, hypertension and diabetes.[36] 
The detection of FH provides added incentive for such patients to optimise treatments for 
these risk factors as well as their FH. Primary prevention of CVD forms part of the everyday 
workload of general practice.[36]  
Primary care, in combination with dedicated specialist lipid clinics, has the potential to offer a 
more cost effective approach that may prove more acceptable to patients and practice staff 
as well as instituting a better disease prevention strategy for affected families. Further 
research is needed to evaluate innovative programs that seek to undertake detection and 
management of index cases at the primary care level as well as providing an approach to 
facilitate cascade testing for newly diagnosed index cases with support from specialist lipid 
clinics for more difficult and hard to manage cases.  
Innovative approaches from primary care  
The importance of developing an acceptable approach to increase detection and diagnosis 
of FH index cases at the primary care level is only partly recognised.[37] An innovative 
approach to opportunistic screening for FH utilising the community laboratory has been 
investigated. GPs request over 90% of the LDL-c levels from a community laboratory.[22] 
Interpretative comments highlighting the possibility of FH were associated with a significant 
additional reduction in LDL-c and increased specialist referrals if such an approach was 
included in the interpretative comment.[23] A phone call between the chemical pathologist 
and requesting primary care physician led to increased specialist assessments, which 
resulted in over 70% of individuals diagnosed with clinical FH.[24] A combined opportunistic 
and retrospective approach using the primary care database needs to be evaluated to 
ascertain acceptance for patients, GPs, PNs, Nurse practitioners (NPs) and practice 
reception staff.  
Potential secondary causes of raised lipids including liver and renal disease, hypothyroidism 
and steroid usage need to be considered and excluded before making a phenotypic 
diagnosis of FH. Central to improving FH care is early identification of the index case or first 
family individual with the diagnosed condition. Cascade testing (family tracing) of index case 
subsequently identifies relatives with FH. A subsequent shared care approach involving lipid 
specialists and GPs can help facilitate cascade testing of index cases to help identify 
relatives with possible FH. 
The current MoC for FH in Australia is designed primarily for lipid clinics in tertiary centres 
[16] but the need to develop a MoC for general practice is recognised.[37] Currently, FH is 
diagnosed through a number of different routes [38] and managed mainly through hospital-
based lipid clinics that may undertake genetic testing particularly if the clinical features are 
highly suggestive of FH. Diagnosis of FH has been shown to prompt action by patients [38] 
and the active involvement of primary care teams in FH identification and optimum 
management is increasingly recognised as the best and most sustainable approach for the 
future.[7] 
There are several tools used worldwide for the phenotypic diagnosis for diagnosingof FH. 
clinically with Due to its ease of clinical use, greater sensitivity and comprehensiveness the 
Dutch Lipid Clinic Network Criteria (DLCNC) score (Figure 1) is the preferred tool of choice 
in Australiaadvocated by the Familial Hypercholesterolaemia Australasia Network 
Consensus Group.[16] The DLCNC score encompasses personal LDL-c levels; personal 
and family history of premature coronary artery and/or vascular disease and physical 
examination to detect tendon xanthomata or premature arcus cornealis.  
The Consensus Statement of the European Atherosclerosis Society [14] and the 
International FH Foundation [39] recommend that most individuals with FH should be treated 
in primary care and preferably in a family context. They advise that more complex cases and 
children with FH should be referred to specialist lipid or FH clinics. The Netherlands (71%) 
and Norway (43%) are leaders in Europe for estimated per cent of individuals known to 
harbour a diagnosis of FH.[14] In the UK, the detection and management of FH has 
improved after the introduction of the NHS Clinical Services initiative.[8] A network of 
regionally located specialist lipid clinics can be accessed by GPs to support primary care 
management.[40] A case ascertainment tool FAMCAT has also been recently produced.[41]   
Cascade testing 
In the Australian setting, an approach through tertiary level specialist centres undertakes 
cascade testing of relatives of index cases. This involves measurement of LDL-c levels, DNA 
testing and statin treatment and has been shown to be cost-effective in preventing CHD.[42] 
However, not all patients at increased risk of FH, including those highlighted in primary care 
setting, end up being referred for specialist assessment.[24] This is likely secondary to the 
low awareness of FH among many health care providers.[15, 43] Costs for the application of 
universal genetic testing to cascade screen relatives of index cases detected in primary care 
could be prohibitive.  However, the application of DLCNC score to detect possible, probable 
and definite adult FH cases should be more feasible with use of LDL-c measurements more 
appropriate for cascade testing children and adults.[16, 44] The DLCNC score can be 
effectively used in primary care to segregate individuals into high and low risk for FH.[45] 
The active involvement of GPs, PNs, NPs and primary care teams could potentially offer a 
much improved detection rate from FH in the community setting. The use of dedicated field 
workers to undertake contact tracing of index cases has been very successful in the 
Netherlands. Other factors including the impact of population migration into Australia are 
likely to reduce the potential to employ a similar approach in this country. In addition, higher 
population densities in smaller geographic areas make logistics of contact tracing easier – 
Netherlands 17 million compares with Australia’s 23 million in land mass just 0.5% of the 
latter. 
Despite these factors, primary care with its ease of access and frequent patient 
consultations offers potential to improve on current detection rates. Increasing awareness 
through health promotion campaigns, highlighting of elevated LDL-c levels on lipid testing 
and help with developing family pedigrees would be essential elements in any future pro-
active approach. A commitment on the part of the primary care team will inevitably be the 
key as any approach that imposes an additional time, manpower or financial burden on the 
practice is likely to be unsustainable in the long run. Building the infra-structure and 
knowledge base from within the practice offers the best long term option for success. The 
UK NICE guidelines [4] have recognised the difficulties of undertaking cascade screening 
from primary care and have suggested the use of specialist lipid clinics to undertake the 
work instead. The use in Australia of the DLCNC score rather than genetic testing to 
establish a diagnosis of FH will make the process easier and offers a better chance of 
success. 
Obtaining consent from index cases to approach relatives about their risk of having FH is 
critical in the cascade testing process.[46] There is extensive evidence to show that 
progressing to family cascade testing would be clinically [4, 14, 16] and financially 
effective.[35, 42, 47]  A diagram to show how to proceed with cascade testing, undertake risk 
notification and suggestions as to how to approach families is shown (Figure 2). If no 
consent is forthcoming and relatives are also patients of the practice, there may be 
opportunities to encourage such relatives to undertake LDL-c testing as part of their regular 
health checks and advise accordingly.[11, 16, 44] Similarly, other relatives who are not 
patients of the practice should be advised by the index case of their potential high FH risk 
and encouraged to have their LDL-c levels assessed at their local practice. Any breach of 
confidentiality should only occur in very specific circumstances such as detailed in the 
relevant jurisdiction. Where uncertainty exists, federal and state government legislation, 
NH&MRC guidelines and local health service protocols about disclosure of medical 
information without consent should be followed. 
It is important, where families and index cases have agreed to co-operate, that the patient’s 
privacy and autonomy are respected and that information concerning the nature of FH that is 
sent or given to a particular individual is transmitted in such a manner that it can be easily 
understood and not cause undue alarm. 
Consultations with relatives should involve pre-test counselling to ensure such patients have 
a good understanding of the nature of the condition and are given an uncomplicated 
explanation as to why early detection for themselves and first degree relatives including 
children might be undertaken, as well as the rationale for treatment if they are shown to have 
FH. It is likely that undertaking a blood test as well as a clinical examination for specific 
features of FH will prove to be more acceptable to patients rather than offering genetic 
testing. Good communication skills and knowledge of the patient and their family background 
should make the process easier for primary care teams. The development of specific skills in 
constructing a family pedigree (Figure 3) and undertaking cascade screening by a specific 
doctor and nurse at a particular practice would be especially valuable for the longer term 
sustainability of the process. 
Management 
Primary care offers a unique opportunity through ease of access and frequent patient 
contact to use a strategy of combining effective patient counselling on the chronic nature of 
FH and the importance of the need for lifelong lipid lowering therapy.  
LDL-c targets: A significant reduction in LDL-c levels is essential to minimise the risk of 
future CVD complications. A reduction of 50% in levels present at diagnosis has been 
suggested with further advice to achieve levels under 3mmol/l and under 2mmol/l 
respectively for those assessed as being in need of more aggressive or intensive 
management. Baseline creatine kinase, liver and kidney function tests can be useful when 
undertaken prior to commencement of statin treatment in these patients as it allows potential 
to compare future levels if patient complains of muscle aches or other symptoms subsequent 
to commencement of statin therapy. In instances where it is difficult to reach recommended 
LDL-c target levels and for higher risk patients newer therapies (such as PCSK9 monoclonal 
antibodies) may be indicated.[48, 49]  
Compliance: Regular patient contact helps to ensure good compliance with medications as 
well as with diet, exercise and other lifestyle modifications. Such a holistic approach is 
essential to ensure lifestyle advice is adhered to and other non-lipid cardiovascular risk 
factors are also addressed. High on the list of priorities would be to target smoking 
cessation. FH patients should be left in no doubt that continuation of smoking by themselves 
or by other family members in their immediate household should not be tolerated under any 
circumstances. 
Rural setting 
Rural GPs and their patients can be considerably disadvantaged by geographical distance 
from specialist lipid clinics. In these circumstances, both patients and doctors have to rely on 
increased use of electronic communications in order to bridge this gap. The use of the 
DLCNC score to achieve a phenotypic diagnosis can be especially useful in these 
circumstances as it facilitates local assessment and risk stratification without having to resort 
to genetic testing at a specialist centre. It is advisable that expert advice should always be 
sought for patients requiring enhanced or intensive management. (Figure 4). A positive 
aspect is the greater local community knowledge of index cases and their extended families 
by GPs which can help facilitate cascade testing of relatives. In addition, the construction of 
family pedigrees (Figure 3) which can be undertaken as part of the contact tracing process 
for newly diagnosed index cases, can help considerably with achieving greater community 
awareness of FH risk. 
Pregnancy 
It is essential that women of childbearing age who have FH are adequately counselled about 
the risks of statin use in pregnancy.[11, 16] All statins and most other lipid modifying drugs 
need to be discontinued for a minimum of three months prior to conception as well as during 
pregnancy and breastfeeding. For FH patients with increased risk of CVD the advice of a 
specialist should be sought to enable a more comprehensive assessment to be undertaken 
while access to lipid specialist support is advised for the duration of a pregnancy.[16, 39, 50, 
51] 
Children and adolescents 
In children and adolescents, a key focus should be on early dietary and lifestyle 
modifications with avoidance of smoking a key area to be targeted. The use of risk 
stratification can help with approaches to treatment but the importance and need for lifetime 
treatment for this cohort needs to be stressed. This message is likely to need ongoing 
reinforcement as the exuberance and indestructability of youth can make compliance with 
strict treatment regimens especially difficult. 
Drug treatment 
Simvastatin, pravastatin, rosuvastatin and fluvastatin are licensed by the Therapeutics 
Goods Authority for use in children in Australia. Primary care physicians may wish to seek 
the advice and support of lipid specialists and/or paediatric cardiologists if they have 
concerns about initiating statin treatment or want additional guidance for this age group and 
their families. Baseline measurements of liver and kidney function as well as creatine kinase 
are advisable for FH children and adolescents. In addition, other developmental aspects 
including growth patterns, body weight as well as sexual and physical maturation should also 
be monitored on a regular basis. 
Family clusters 
The probability exists that other siblings and first degree relatives will also have FH and in 
such circumstances it may be possible to arrange for management and follow-up of such 
family clusters to be undertaken at a specialised FH clinic either in primary care setting or 
with support from tertiary level lipid clinic. For those patients requiring more intensive 
management – especially those who are homozygous or compound heterozygous as well as 
those refractory or intolerant of cholesterol lowering medications – the option of LDL-
apheresis needs to be considered and advice sought from lipid specialist with experience in 
the area.  
Conclusions 
There is increasing awareness worldwide that despite various strategies to increase 
detection of FH, most people with the disorder remain undetected and untreated. It is equally 
well known that for affected patients to get the best possible outcome for the condition it is 
imperative that the diagnosis of FH is made early, preferably in childhood, adolescence [5] or 
young adulthood. Improved education, especially for younger FH patients, greater 
community awareness of the disorder including that of specialists, GPs, PNs, NPs and 
primary care teams, together with an ongoing chronic disease management plan with regular 
review visits, are seen as essential to achieve adherence to life-long treatment. 
Newer evidence suggests that the prevalence in Australia is about 1:200-300 [9-11] yielding 
a total population of 80,000 nationwide with the overwhelming majority remaining 
unrecognised. It is hoped that improved community screening programmes, involving 
targeted, universal and cascade testing and better integration of specialist and primary care, 
will play a major role in redressing this shortfall. 
The diagnosis of FH is cost-effective and presents the greatest opportunity to reduce the 
overall CVD burden. GPs and primary care teams need to be alert and recognise that raised 
LDL-c together with personal or family history of premature vascular disease may indicate 
FH. The use of absolute cardiovascular risk calculations are not appropriate for this 
population group as they are already at high risk of CVD. 
The DLCNC score is an effective tool to achieve a phenotypic diagnosis of FH in primary 
care setting in Australia, but secondary causes of hypercholesterolaemia need to be 
excluded. Once an index case is recognised in primary care, cascade testing of relatives 
should be undertaken and assistance sought from specialist lipid clinics as necessary.  
Expert Commentary 
Familial hypercholesterolaemia has a poor public awareness profile in Australia among both 
patients and medical practitioners. In comparison with the Netherlands where 71% of 
affected patients are diagnosed, only 1% of Australian FH patients are currently detected. 
Based on recent evidence from Denmark, [9] it is likely that up to half of the patients known 
to have FH are not being treated appropriately. 
Currently, most of the diagnosis and management of FH in Australia occurs in tertiary level 
specialist centres. It is felt that shifting the detection and management into the primary care 
sector has the potential to radically alter the management of the condition while still 
maintaining the option of specialist involvement for more complex and hard to manage 
patients. In addition, the use of genetic testing for DNA mutations is costly and not all 
mutations can be detected. The use of the DLCNC score offers a more primary care friendly 
approach to achieve a phenotypic diagnosis and offers a greater likelihood for a sustainable 
model in primary care. 
A key plank in this approach will be to increase both patient and medical practitioner 
awareness of the condition and thereby facilitate improved diagnoses. The use of labour 
saving data extraction tools on general practice databases has the potential to alert primary 
care teams to those patients attending the practice considered to have increased risk of FH.  
Such patients can then be systematically reviewed by their GPs who can use the opportunity 
of recall visits to update personal and family history, undertake physical examination and 
apply the DLCNC score to establish a phenotypic diagnosis of FH. 
The subsequent MoC will involve identification of the index cases in primary care, the 
provision of advice on institution and continuation of appropriate dietary and lifestyle 
modifications, a discussion on commencement of lifelong drug treatment, the construction of 
family pedigree trees and the application of cascade testing of their first degree relatives.  
The sustainability of the proposed MoC in the Australian primary care setting lies in the 
recognition of FH as a lifelong, chronic condition that is ideally suited to Care Plan 
development and follow-up with involvement of allied health support in ongoing patient 
management. The ease of access and frequent patient contact in primary care will help 
facilitate this approach. Specialist help should still remain available for higher complexity 
patients. This MoC could be adapted for use in other countries.  
As part of this proposed policy shift from tertiary level care to primary care, we are 
undertaking research Australia wide that employs data extraction techniques to identify high 
risk patients, apply the DLCNC score, estimate FH complexity, institute appropriate drug and 
lifestyle treatment and undertake cascade testing of relatives. The hope is to provide 
scientific evidence that our proposed model of care works in the busy clinical practice setting 
and that it becomes embedded and sustainable into the future. Key outcomes for this will 
include increased awareness about FH among patients and primary care teams, improved 
confidence in detection and management, increasing numbers of index cases and relatives 
subsequently diagnosed and appropriate responses to treatment reflected in LDL-c levels.  
 
Five-year view 
The use of targeted data extraction from existing electronic medical records could help 
identify patients at high risk of FH in the community setting. A sustainable method tailored to 
the needs of primary care could help with community based detection and treatment. An 
integrated care program in primary care involving key GPs, PNs and NPs with specialist help 
as needed, would be ideal. Further assistance from lipid specialists for more difficult to 
control and complex cases, pregnant women and children will still be required. High risk 
patients, including those intolerant or inadequately managed on standard treatment, may 
require newer therapies in addition to statins.  
Key issues 
•  General community awareness of the potential for FH among patients, primary care 
physicians, cardiologists and other health professionals is low and needs to be improved 
if optimum management is to be achieved. 
• The prevalence of FH is now recognised as about 1 in 250 compared to the 1 in 500 
reported in the past. 
• Using genetic testing to confirm a clinical suspicion of FH may not be conclusive as up 
to 40% of individuals tested will not have a positive result for a mutation. 
• The Dutch Lipid Clinic Network Criteria score offers another approach that achieves a 
phenotypic diagnosis without having to undertake expensive genetic testing for all 
patients. 
• Children, adolescents and young adults have most to gain from the early detection and 
appropriate management of FH. 
• Once an index case for FH has been identified in the community, a process to initiate 
contact tracing and cascade testing of relatives should be implemented at the primary 
care level. 
• Undertaking cascade testing in the community setting will involve developing a 
sustainable approach delivered through primary care teams with specialist support and 
advice for patients requiring more intensive management. 
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Reference Annotations 
*Of interest 
3. Useful overview of the extent of problem that FH presents. 
5. Good paper highlighting the benefits that can be gained from early diagnosis and 
treatment of FH in children and adolescents. 
6. Helpful systematic review that focusses on the cost effectiveness of diagnosing and 
treating FH. 
11. This paper shows the prevalence of FH in Australian population is considerably higher 
than previously reported. 
39. Useful paper highlighting the benefits from using an integrated approach for FH 
management. 
  
** Of considerable interest 
14. Useful consensus statement that highlights the under-diagnosis and under-treatment of
FH among the general population.
16. Good overview of current clinical problem in Australasia with helpful information on
model of care for FH. 
25. This paper provides a helpful introductory primary care perspective with advice on how
to approach detection of FH in the community.
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